Why Is Theriva Biologics Stock Gaining Monday?
I'm PortAI, I can summarize articles.
Theriva Biologics, Inc. (TOVX) stock rose 4.03% on Monday, with a volume of 114.18 million shares. The increase follows the company's receipt of Scientific Advice from the EMA's CHMP regarding a Phase 3 trial for VCN-01, aimed at treating metastatic pancreatic ductal adenocarcinoma (PDAC). The trial will assess VCN-01 in combination with standard chemotherapy. The CHMP acknowledged the positive results from the VIRAGE phase 2 trial, which showed improved survival rates for patients receiving VCN-01. Theriva has $15.5 million in cash, providing a runway into early 2027.
Source: fidelity The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments